Pertzye Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to rising prevalence of cystic fibrosis-related epi, increased diagnosis of chronic pancreatitis, clinical validation of pancrelipase formulations, expansion of gastroenterology treatment protocols, improved awareness of malabsorption disorders.

The growth in the forecast period can be attributed to expansion of personalized digestive care, rising adoption of advanced enzyme formulations, increasing focus on long-term epi management, growing demand for high-strength enzyme variants, continued innovation in drug delivery coatings. Major trends in the forecast period include increasing use of pancreatic enzyme replacement therapies, growing demand for buffered enteric coatings, expansion of chronic epi management programs, enhanced focus on digestive efficacy, improved patient adherence through formulation innovation.

The rising prevalence of chronic pancreatitis is expected to drive the growth of the Pertzye market in the future. Chronic pancreatitis is a long-term inflammation of the pancreas that causes irreversible damage, digestive issues, and potential complications like diabetes. The increasing prevalence of chronic pancreatitis is linked to factors such as excessive alcohol consumption, genetic predisposition, autoimmune disorders, and long-term obstruction of the pancreatic ducts caused by gallstones or tumors. Pertzye helps manage chronic pancreatitis by supplying essential pancreatic enzymes that aid in digestion and alleviate symptoms of malabsorption in patients with exocrine pancreatic insufficiency. For example, in August 2023, a population-based epidemiology study published in the World Journal of Gastroenterology, a China-based journal, reported that the point prevalence of chronic pancreatitis in Sichuan Province, China, reached 45.52 per 100,000 individuals. Thus, the growing prevalence of chronic pancreatitis is contributing to the expansion of the Pertzye market.

The growing emphasis on personalized medicine is expected to drive the growth of the Pertzye market in the future. Personalized medicine is an approach to healthcare that tailors treatment based on an individual's genetic, environmental, and lifestyle factors to optimize outcomes and improve effectiveness. This growing focus on personalized medicine is fueled by advancements in genomics and biotechnology, which allow for more precise treatments tailored to an individual’s genetic profile, enhancing patient outcomes and minimizing adverse effects. Pertzye, an enzyme replacement therapy, supports personalized medicine by offering tailored treatment for individuals with cystic fibrosis who experience pancreatic insufficiency, improving digestion and nutrient absorption based on their specific needs. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a notable increase from the six approved in 2022. As a result, the growing focus on personalized medicine is contributing to the growth of the Pertzye market.

The increasing incidence of digestive disorders is also expected to fuel the growth of the Pertzye market. Digestive disorders encompass a range of conditions that affect the normal functioning of the digestive system, including the stomach, intestines, and related organs. The rise in digestive disorders is attributed to factors such as poor diet, stress, sedentary lifestyles, and environmental toxins, leading to conditions like irritable bowel syndrome (IBS), acid reflux, and inflammatory bowel diseases (IBD). Pertzye assists in managing digestive disorders by providing pancreatic enzymes that help break down fats, proteins, and carbohydrates, improving digestion in individuals with pancreatic insufficiency. For instance, in December 2023, the IBD Registry, a UK-based non-profit organization, reported that by 2023, it had reached over 5,300 individuals with inflammatory bowel disease (IBD), an increase of more than 3,000 members compared to 2022. Therefore, the rise in digestive disorders is driving the growth of the Pertzye market.

Major companies operating in the pertzye market are Digestive Care Inc.

North America was the largest region in the pertzye market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pertzye market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pertzye market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the pertzye market by increasing costs of imported pharmaceutical excipients, encapsulation materials, coating technologies, and enzyme processing equipment. North America and Europe are most affected due to reliance on specialized imported formulation inputs, while Asia-Pacific faces cost pressure on finished drug exports. These tariffs are increasing manufacturing and distribution costs. At the same time, they are supporting localized pharmaceutical production, regional sourcing of excipients, and investments in domestic drug formulation capabilities.

The pertzye market research report is one of a series of new reports that provides pertzye market statistics, including pertzye industry global market size, regional shares, competitors with a pertzye market share, detailed pertzye market segments, market trends and opportunities, and any further data you may need to thrive in the pertzye industry. This pertzye market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pertzye is a medication containing pancrelipase, a combination of lipase, protease, and amylase enzymes. It is used to treat exocrine pancreatic insufficiency (EPI), a condition in which the pancreas is unable to produce sufficient enzymes for proper digestion. Pertzye is uniquely formulated with a bicarbonate-buffered enteric coating, which helps deliver the enzymes to the small intestine, where they can effectively aid in the digestion of fats, proteins, and carbohydrates.

The primary indications for Pertzye include exocrine pancreatic insufficiency (EPI) due to cystic fibrosis, chronic pancreatitis, pancreatitis surgery, and other related conditions. EPI in cystic fibrosis is a condition where the pancreas fails to produce enough digestive enzymes, leading to nutrient malabsorption, which is commonly treated with pancreatic enzyme replacements such as Pertzye. The medication is available in various formulations, including delayed-release capsules and different strength variants, and is distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

The pertzye market consists of sales of pancrelipase. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.